Accepted Manuscript

Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance

Qi-Nian Wu, Yi-Fu Liao, Yun-Xin Lu, Yun Wang, Jia-Huan Lu, Zhao-Lei Zeng, Qi-Tao Huang, Hui Sheng, Jing-Ping Yun, Dan Xie, Huai-Qiang Ju, Rui-Hua Xu

PII: S0304-3835(17)30631-6

DOI: 10.1016/j.canlet.2017.10.007

Reference: CAN 13550

To appear in: Cancer Letters

Received Date: 18 July 2017

Revised Date: 29 September 2017

Accepted Date: 9 October 2017

Please cite this article as: Q.-N. Wu, Y.-F. Liao, Y.-X. Lu, Y. Wang, J.-H. Lu, Z.-L. Zeng, Q.-T. Huang, H. Sheng, J.-P. Yun, D. Xie, H.-Q. Ju, R.-H. Xu, Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance, *Cancer Letters* (2017), doi: 10.1016/j.canlet.2017.10.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Pharmacological inhibition of DUSP6 suppresses gastric

cancer growth and metastasis and overcomes cisplatin

resistance

Qi-Nian Wu ^{a,1}, Yi-Fu Liao ^{c,1}, Yun-Xin Lu ^{a,1}, Yun Wang ^a, Jia-Huan Lu ^a, Zhao-Lei Zeng ^a, Qi-Tao Huang ^a, Hui Sheng ^a, Jing-Ping Yun ^b, Dan Xie ^a, Huai-Qiang Ju ^{a*}, and Rui-Hua Xu ^{a*}

^a Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China;

^b Sun Yat-sen University Cancer Center, department of pathology, Guangzhou, 510060, China

^c Guangdong General Hospital, Guangdong Neuroscience Institute, Guangdong Academy of Medical Sciences, Department of Neurology, Guangzhou, 510080, China.

¹ These authors contributed equally to this work.

* Correspondence: Rui-Hua Xu, E-mail: <u>xurh@sysucc.org.cn</u>; Huai-Qiang Ju, E-mail: juhq@sysucc.org.cn. Address: 651 Dongfeng East Road,

Guangzhou 510060, China; Tel: +86-20-8734-3228; Fax: +86-20-8734-3392;

Abstract

Gastric cancer (GC) is the second cause of cancer-related death. Cisplatin (CDDP) is widely used as the standard GC treatment, but relapse and metastasis are common because of intrinsic or acquired drug resistance. The mitogen-activated protein kinase phosphatases (MAPK)-extracellular signal regulated kinases (ERK) pathway contributes to GC progression and drug resistance, but targeting the MAPK-ERK pathway is challenging in GC therapy. Here, we demonstrated that dual-specificity phosphatases 6 (DUSP6) was overexpressed in GC and predicted poor overall survival and progression-free survival. Knockdown DUSP6 inhibited GC proliferation, migration, invasion and induced apoptosis. (E/Z)-BCI hydrochloride (BCI), a DUSP6 small molecule inhibitor, increased the activity of ERK but interestingly decreased the expression of ERK response genes in BGC823, SGC7901 and CDDP-resistant SGC7901/DDP cells. BCI also caused cell death through the DNA damage response (DDR) pathway. Moreover, BCI inhibited cell proliferation, migration and invasion in a receptor-independent manner and enhanced CDDP cytotoxicity at pharmacological concentrations in the GC cells. In vivo experiments further showed that BCI enhances the antitumor effects of CDDP in cell-based xenografts and PDX models. In summary, our findings indicated that disruption of DUSP6 by BCI enhanced CDDP-induced cell death and apoptosis in GC may partly through ERK and DDR pathways. Thus, this study suggests that DUSP6 is a potential prognostic biomarker and a promising target for GC therapy.

Download English Version:

https://daneshyari.com/en/article/8435122

Download Persian Version:

https://daneshyari.com/article/8435122

Daneshyari.com